Merck, Moderna Stocks Soar After Melanoma Trial Success
Moderna and Merck's stock prices surged following positive results from a late-stage clinical trial of their jointly developed mRNA vaccine for melanoma. The vaccine demonstrated promising efficacy in reducing melanoma recurrence in patients. This breakthrough represents a significant advancement in using mRNA technology to treat skin cancer.
1 Article
Trace's outlet lean is shown first — tap Left / Center / Right on each source to add your rating too.
- BloombergTrace: Center
Merck, Moderna Stocks Soar After Melanoma Trial Success
Moderna and Merck's stock prices surged following positive results from a late-stage clinical trial of their jointly developed mRNA vaccine for melanoma. The vaccine demonstrated promising efficacy in reducing melanoma recurrence in patients. This breakthrough represents a significant advancement in using mRNA technology to treat skin cancer.
Rate outletRead original
Readers say
How does this story lean?
Outlet ratings above are Trace's curated source map. Vote here (same as on the home feed) — one vote per browser, changeable anytime. Rate individual outlets in the coverage list below.
Comments
0No comments yet. Say what you noticed in the coverage.
Trending